A next-generation T cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies, delivering robust, sustained, and safer immune responses against solid tumors.

An advanced cell armoring platform that enhances ACT therapies by equipping them to overcome TME barriers and heterogeneity, improving safety, infiltration, and persistence in solid tumors.

An AI-powered high-throughput platform that rapidly discovers therapeutic TCRs by integrating single-cell transcriptomic and functional analysis, significantly cutting time and cost in TCR-based drug development.

Industrial-scale clinical-grade vector and engineered immune cell production serves as the foundation for clinical development capabilities in immune cell therapy.